KR20250065944A - 악성종양을 치료하기 위한 복합 요법 - Google Patents

악성종양을 치료하기 위한 복합 요법 Download PDF

Info

Publication number
KR20250065944A
KR20250065944A KR1020257014978A KR20257014978A KR20250065944A KR 20250065944 A KR20250065944 A KR 20250065944A KR 1020257014978 A KR1020257014978 A KR 1020257014978A KR 20257014978 A KR20257014978 A KR 20257014978A KR 20250065944 A KR20250065944 A KR 20250065944A
Authority
KR
South Korea
Prior art keywords
day
compound
dosage
specific
cytarabine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257014978A
Other languages
English (en)
Korean (ko)
Inventor
사무엘 브이. 아그레스타
Original Assignee
르 라보레또레 쎄르비에르
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 르 라보레또레 쎄르비에르 filed Critical 르 라보레또레 쎄르비에르
Publication of KR20250065944A publication Critical patent/KR20250065944A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020257014978A 2015-10-15 2016-10-14 악성종양을 치료하기 위한 복합 요법 Pending KR20250065944A (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562242256P 2015-10-15 2015-10-15
US62/242,256 2015-10-15
US201562255194P 2015-11-13 2015-11-13
US62/255,194 2015-11-13
PCT/US2016/057083 WO2017066599A1 (en) 2015-10-15 2016-10-14 Combination therapy for treating malignancies
KR1020187010260A KR20180063125A (ko) 2015-10-15 2016-10-14 악성종양을 치료하기 위한 복합 요법

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020187010260A Division KR20180063125A (ko) 2015-10-15 2016-10-14 악성종양을 치료하기 위한 복합 요법

Publications (1)

Publication Number Publication Date
KR20250065944A true KR20250065944A (ko) 2025-05-13

Family

ID=57208385

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020257014978A Pending KR20250065944A (ko) 2015-10-15 2016-10-14 악성종양을 치료하기 위한 복합 요법
KR1020187010260A Ceased KR20180063125A (ko) 2015-10-15 2016-10-14 악성종양을 치료하기 위한 복합 요법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020187010260A Ceased KR20180063125A (ko) 2015-10-15 2016-10-14 악성종양을 치료하기 위한 복합 요법

Country Status (15)

Country Link
US (2) US10905692B2 (https=)
EP (2) EP3362057A1 (https=)
JP (2) JP2018534288A (https=)
KR (2) KR20250065944A (https=)
CN (1) CN108366980A (https=)
AU (1) AU2016340087C1 (https=)
BR (1) BR112018007304A2 (https=)
CA (1) CA3001599A1 (https=)
CL (1) CL2018000927A1 (https=)
EA (1) EA201890968A1 (https=)
IL (2) IL311873A (https=)
MX (2) MX394796B (https=)
SG (1) SG10201912886XA (https=)
WO (1) WO2017066599A1 (https=)
ZA (1) ZA201802088B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015324158A1 (en) 2014-09-29 2017-04-13 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CN107531675A (zh) 2015-02-04 2018-01-02 安吉奥斯医药品有限公司 治疗活性化合物及其使用方法
US10695352B2 (en) 2015-10-15 2020-06-30 Celgene Corporation Combination therapy for treating malignancies
US12064445B2 (en) 2015-12-03 2024-08-20 Biosight Ltd. Cytarabine conjugates for cancer therapy
MX392941B (es) 2016-09-07 2025-03-24 Celgene Corp Composiciones para comprimidos.
WO2018204787A1 (en) 2017-05-05 2018-11-08 Memorial Sloan Kettering Cancer Center Methods of treatment of myeloproliferative neoplasm
WO2019012328A1 (en) * 2017-07-09 2019-01-17 Biosight Pharma ANTICANCER POLY THERAPY
US10980788B2 (en) * 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
WO2020092894A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl) pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol
WO2020092906A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof
WO2020092915A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Solid dispersions for treatment of cancer
WO2021097160A1 (en) 2019-11-14 2021-05-20 Celgene Corporation Pediatric formulations for treatment of cancer
CN111087408B (zh) * 2020-01-03 2021-04-02 浙江大学 一种大环结构的idh2突变体抑制剂及其医药用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2290624C (en) 1997-06-06 2006-12-05 John W. Shell Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
ES2270982T3 (es) 2000-02-04 2007-04-16 Depomed, Inc. Forma de dosificacion de nucleo y carcasa que se aproxima a una liberacion del farmaco de orden cero.
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
AU2010223919B2 (en) 2009-03-13 2016-03-31 Les Laboratoires Servier Methods and compositions for cell-proliferation-related disorders
WO2011050211A2 (en) * 2009-10-21 2011-04-28 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
NZ627096A (en) 2012-01-06 2017-02-24 Agios Pharmaceuticals Inc Triazinyl compounds and their methods of use
MY185687A (en) 2013-07-11 2021-05-30 Agios Pharmaceuticals Inc N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer
TWI666208B (zh) 2013-08-02 2019-07-21 美商阿吉斯藥品有限公司 治療活性化合物及其使用方法（三）
WO2015018060A1 (en) 2013-08-09 2015-02-12 Agios Pharmaceuticals, Inc. Crystalline forms of therapeutically active compounds and use thereof
AU2015324158A1 (en) 2014-09-29 2017-04-13 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CN107531675A (zh) 2015-02-04 2018-01-02 安吉奥斯医药品有限公司 治疗活性化合物及其使用方法
CA2993615A1 (en) 2015-08-05 2017-02-09 Agios Pharmaceuticals, Inc. Methods of preparing 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diols and 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diamines
US10695352B2 (en) 2015-10-15 2020-06-30 Celgene Corporation Combination therapy for treating malignancies
IL298663A (en) 2015-12-04 2023-01-01 Agios Pharmaceuticals Inc Methods for treating acute myeloid leukemia characterized by the presence of a mutant allele of idh2 and the absence of a mutant allele of nras
ES2912909T3 (es) 2016-02-26 2022-05-30 Celgene Corp Enasidenib para su uso en el tratamiento de la leucemia mieloide aguda recidivante o refractaria

Also Published As

Publication number Publication date
MX394796B (es) 2025-03-24
NZ740792A (en) 2024-05-31
KR20180063125A (ko) 2018-06-11
AU2016340087A1 (en) 2018-04-12
CA3001599A1 (en) 2017-04-20
MX2022006701A (es) 2022-07-12
EP4147692A1 (en) 2023-03-15
SG10201912886XA (en) 2020-02-27
US10905692B2 (en) 2021-02-02
IL311873A (en) 2024-06-01
JP2021130682A (ja) 2021-09-09
ZA201802088B (en) 2021-07-28
BR112018007304A2 (pt) 2018-10-23
CL2018000927A1 (es) 2018-09-14
US20180311249A1 (en) 2018-11-01
CN108366980A (zh) 2018-08-03
AU2016340087C1 (en) 2022-08-18
EA201890968A1 (ru) 2018-09-28
US20210386749A1 (en) 2021-12-16
MX2018004595A (es) 2019-07-04
AU2016340087B2 (en) 2022-05-12
JP2018534288A (ja) 2018-11-22
EP3362057A1 (en) 2018-08-22
IL258269A (en) 2018-05-31
WO2017066599A1 (en) 2017-04-20

Similar Documents

Publication Publication Date Title
US20210386749A1 (en) Combination therapy for treating malignancies
US10137130B2 (en) Methods of treatment of malignancies
US10188656B2 (en) Methods of treatment of malignancies
US10695352B2 (en) Combination therapy for treating malignancies
US11419859B2 (en) Combination therapy for treating malignancies
EP3493809B1 (en) Enasidenib for treatment of myelodysplastic syndrome
JP7093764B2 (ja) 骨髄異形成症候群の治療方法
HK40114599A (en) Combination therapy for treating malignancies
EA039805B1 (ru) Комбинированная терапия для лечения злокачественных опухолей

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20250507

Application number text: 1020187010260

Filing date: 20180411

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250520

Comment text: Request for Examination of Application